Risikoen for kumulativ knoglemarvssuppression skal overvejes som med andre cytotoksiske behandlinger, når gemcitabin gives sammen med anden kemoterapi.
As with other cytotoxic treatments, the risk of cumulative bone-marrow suppression must be considered when gemcitabine treatment is given together with other chemotherapy